Ovarian Carcinoma
Conditions
Keywords
chemoprevention, green tea, relapse free-survival, proteases
Brief summary
Green tea is extracted from steam treated leaves, allowing the preservation of catechins, the active elements of the infusion. Catechins are recognized for their anti-cancer activity. Catechins act on the capacity of cancer to disseminate to other organs because of their anti-protease action. Proteases are proteins capable of digesting the cancer environment and facilitating the progression of cancer cells to blood vessels which will bring them to distant organs. We know that ovarian cancer responds well to the initial treatment of chemotherapy but tends to recur rapidly. We intend to provide green tea with higher concentrations of catechins to women with complete remission of their ovarian cancer in an attempt to delay cancer relapse. We also intend to identify, with molecular technologies, the proteases involved in ovarian cancer recurrence and response to catechins. Our objective is to test the hypothesis that green tea intake may delay ovarian cancer recurrence and to develop tools to predict which women will best benefit of the addition of green tea to their initial treatment.
Interventions
DIETARY_SUPPLEMENTDouble-Brewed Green Tea
liquid, 4 celsius; 500 mL ID, 3 hours after meals and 1 hour before next meal; duration: to the first of the following events: 18 months or relapse
Sponsors
Cancer Research Society
CHU de Quebec-Universite Laval
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Healthy volunteers
No
Inclusion criteria
* patients with ovarian serous carcinoma FIGO stage III or IV * patients showing complete response after oncological surgery and chemotherapy (paclitaxel-carboplatin, minimum 5 cycles, maximum 8 cycles), complete response being defined as 1) a negative complete physical examination 2) Serum CA-125 levels inferior to 35 U/mL 3) no evidence of diseased assessed by abdomino-perineal CT-scan * patients refraining from drinking tea other than provided by the study * patients who may absorb liquids orally * patients without any other malignancy (except for non-melanoma skin cancer) * patients not involved in an other study * patients who signed up informed consent form.
Exclusion criteria
*
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| time to relapse | 36 months |
Secondary
| Measure | Time frame |
|---|---|
| toxicity | 14th and 28th patients recruted and PRN |
Countries
Canada
Outcome results
None listed